High-concentration monoclonal antibody (mAb) formulations (≥100 mg/mL) have emerged as a predominant formulation modality for subcutaneous delivery, enabling patient self-administration and significantly improving clinical compliance. However, concentration-dependent viscosity elevation remains a pivotal technical challenge that restricts the manufacturability, administerability, and shelf-life stability of high-dose mAb products. The rheological deterioration is fundamentally driven by intensified intermolecular interactions under crowded molecular environments. As protein molecular spacing diminishes drastically at elevated concentrations, non-covalent attractive forces—including hydrophobic interaction, hydrogen bonding, and electrostatic attraction—prevail in the solution system, compromising fluidity and inducing a cascade of adverse outcomes in clinical application, biomanufacturing, and product quality stability.
Clinically, excessive solution viscosity increases the extrusion force required for prefilled syringe operation, rendering self-injection infeasible for elderly patients and individuals with arthritic conditions. The mandatory adoption of larger-gauge needles further exacerbates injection pain and poor patient experience. In bioprocessing, high viscosity elevates axial pressure drop during ultrafiltration/diafiltration (UF/DF), imposing an upper limit on the final achievable protein concentration. It also compromises sterile filtration flux, reduces filling precision, and disrupts process consistency. Furthermore, elevated viscosity is strongly correlated with enhanced protein aggregation propensity, which jeopardizes the long-term physicochemical stability of mAb therapeutics. For subcutaneous mAb formulations, the clinically acceptable viscosity range is typically 10–20 cP, with an optimal threshold below 10 cP to guarantee satisfactory injectability and patient tolerability. Accordingly, the establishment of robust viscosity modulation strategies is indispensable for the successful development and commercialization of high-concentration mAb formulations. This review comprehensively elaborates on the well-characterized and industrially viable viscosity reduction approaches for high-density antibody solutions.
1. pH Adjustment
pH tuning represents one of the most direct and efficacious strategies for mitigating the viscosity of high-concentration mAb solutions, with its working mechanism rooted in the modulation of surface net charge and intermolecular electrostatic repulsion. The isoelectric point (pI) of most IgG-type antibodies falls within the range of 7.0–9.0. When the solution pH deviates from the molecular pI, mAb molecules carry abundant net positive or negative surface charges, generating robust electrostatic repulsion that suppresses molecular aggregation and close intermolecular contact, thereby reducing bulk solution viscosity. Conversely, pH conditions proximal to the antibody pI neutralize surface net charge, eliminate electrostatic repulsive forces, and allow attractive intermolecular interactions to dominate, resulting in pronounced viscosity augmentation.
For canonical IgG molecules with a pI of approximately 8.5, the pH range of 5.5–6.5 generally confers minimal solution viscosity. pH optimization must be performed in tandem with stability profiling to balance rheological performance and product quality. Extremely acidic conditions (pH < 5.0) accelerate chemical degradation pathways such as deamidation and protein aggregation, while excessively alkaline environments (pH > 8.0) trigger oxidative modification and polypeptide fragmentation. In conventional formulation development, a pH gradient spanning 5.0–7.0 is systematically screened, and the optimal formulation pH is determined via integrated evaluation of rheological properties and accelerated stability data. As a representative case, an 8.2 pI mAb exhibits a solution viscosity of 15 cP at pH 6.0, which declines to 8 cP at pH 5.0 while retaining favorable chemical stability. Notably, the viscosity-modulating efficacy of pH adjustment is highly molecule-specific, dictated by the intrinsic amino acid sequence and surface charge distribution of individual antibodies.
2. Arginine Supplementation
L-Arginine is a gold-standard functional excipient for viscosity reduction in high-concentration mAb formulations, acting via dual modulation of electrostatic and hydrophobic intermolecular forces. The positively charged guanidinium group of arginine engages in electrostatic pairing with negatively charged surface domains of mAb molecules, while its aliphatic hydrophobic moiety shields exposed hydrophobic patches on the protein surface. This dual shielding effect effectively attenuates dominant attractive intermolecular interactions, thereby lowering solution viscosity. Multiple quantitative studies have validated that supplementation with 50–200 mM arginine reduces the viscosity of 150–200 mg/mL mAb solutions by 30%–60%.
Arginine hydrochloride is the most widely utilized salt form in pharmaceutical formulation development due to its superior aqueous solubility and minimal pH perturbation. In a typical industrial case, a 200 mg/mL IgG formulation exhibits a viscosity of 45 cP in the absence of arginine, which is reduced to 22 cP upon supplementation with 100 mM arginine hydrochloride. Correspondingly, the injection extrusion force decreases from 35 N to 18 N, satisfying the operational specifications of commercial auto-injection devices. Despite its prominent rheological benefits, several application constraints require rigorous assessment. Arginine may alter the long-term conformational and chemical stability of mAbs, necessitating comprehensive accelerated and real-time stability validation. Supraphysiological arginine concentrations (>200 mM) elevate solution osmolality, which may induce local injection site irritation and adverse tissue reactions. Moreover, arginine can be synergistically combined with pH optimization or proline supplementation to achieve superior viscosity-lowering outcomes. Additionally, chloride ions dissociated from arginine hydrochloride pose potential corrosion risks to stainless steel manufacturing equipment, requiring vigilant process control.
3. Proline Supplementation
L-Proline, a naturally occurring cyclic amino acid, possesses distinct merits as a high-efficiency viscosity-modulating excipient for high-concentration mAb formulations, including superior rheological efficacy, excellent biocompatibility, and high chemical inertness. Similar to arginine, proline alleviates solution viscosity through hydrophobic shielding and electrostatic repulsion enhancement. Its unique pyrrolidine cyclic structure endows proline with stronger hydrophobic domain masking capability and higher resistance to chemical degradation compared with linear amino acids.
Quantitative rheological tests confirm that proline exhibits concentration-dependent viscosity reduction efficacy superior to that of equivalent arginine. Supplementation of 200 mM proline reduces the viscosity of a 150 mg/mL mAb solution from 30 cP to 12 cP, representing a 60% viscosity reduction. For 200 mg/mL IgG formulations, 200 mM proline achieves approximately 50% viscosity attenuation without compromising antibody conformational integrity. Beyond rheological regulation, proline serves as a dual-functional excipient that concurrently enhances protein colloidal stability and anti-aggregation capacity. It induces milder osmolality elevation than other amino acid additives, demonstrates chemical compatibility with conventional formulation components, and eliminates equipment corrosion risks due to its chloride-free nature. The optimal working concentration of proline ranges from 100 to 250 mM, requiring synergistic optimization with buffer composition and solution pH. Given the molecule-specific responsiveness of mAbs to proline modulation, proline screening should be integrated into early-stage formulation candidate evaluation workflows.
4. Salt Additives
Inorganic salt additives (e.g., NaCl, Na₂SO₄, MgCl₂) exert non-monotonic, concentration-dependent rheological effects on high-concentration mAb solutions, displaying U-shaped or inverted U-shaped viscosity profiles that are contingent on salt type, ionic strength, and intrinsic protein physicochemical properties. At low ionic strength (<50 mM), dissociated inorganic ions shield intermolecular electrostatic attraction between oppositely charged surface residues of mAb molecules, thereby reducing solution viscosity, particularly for neutral-pI mAb systems dominated by electrostatic intermolecular interactions.
At moderate salt concentrations (50–150 mM), the rheological outcome is highly antibody-dependent. For mAb solutions governed by hydrophobic intermolecular forces, moderate ionic strength exacerbates hydrophobic aggregation via the salting-out effect, leading to viscosity elevation. At high ionic strength (>200 mM), substantial viscosity augmentation is universally observed, as excessive ions completely screen intermolecular electrostatic repulsion and render hydrophobic attraction the dominant intermolecular force. Different inorganic salts exhibit divergent modulation characteristics: Na₂SO₄ acts as a potent salting-out agent that amplifies hydrophobic interactions and tends to increase solution viscosity, whereas NaCl exhibits salting-in behavior and delivers more favorable viscosity reduction in most mAb formulation systems.
For novel mAb formulation development, a NaCl concentration gradient of 0–300 mM should be systematically screened at the target high concentration, with the optimal ionic strength determined via multivariate evaluation of rheological performance and stability attributes. In cases where inorganic salts induce unfavorable viscosity elevation, amino acid-based excipients such as arginine are preferred alternative modulators. Additionally, salt-induced elevation of solution osmolality may provoke injection-site pain and irritation, which requires comprehensive risk assessment during formulation optimization.
5. Surfactants
Nonionic surfactants, typically polysorbate 20 and polysorbate 80, exert negligible direct impacts on the bulk rheological properties of high-concentration mAb solutions. Owing to their low working dosage (0.01–0.1 mg/mL) and small molecular dimension, surfactants preferentially partition at gas-liquid and solid-liquid interfaces rather than altering the viscous behavior of the bulk protein solution. Previous rheological studies have verified that supplementation of 0.02% polysorbate 80 into 150 mg/mL IgG solutions induces a viscosity variation of less than 5%, confirming their minimal direct viscosity-modulating capacity.
Nevertheless, surfactants improve the manufacturability and clinical applicability of high-concentration mAb formulations via indirect protective mechanisms. They mitigate interfacial tension, suppress protein denaturation and aggregation at phase interfaces, and eliminate shear thickening and localized hyperviscosity triggered by bubble formation and microcavitation during manufacturing and administration. Furthermore, surfactants inhibit storage-induced protein aggregation, thereby preventing time-dependent viscosity elevation. Functionally, surfactants reduce syringe extrusion force by lubricating the contact interface between syringe barrels and rubber stoppers; however, this mechanical lubrication effect does not alter the intrinsic bulk viscosity of the mAb solution.
In systematic formulation design, surfactants are classified as auxiliary protective excipients rather than primary viscosity modulators. Core viscosity optimization relies on pH manipulation, amino acid supplementation, and ionic strength tuning. Surfactant dosage requires precise optimization to balance interfacial protection and formulation safety: insufficient concentrations fail to provide effective interfacial stabilization, while excessive dosing may induce micelle formation, compromise solution homogeneity, and elicit potential hemolytic risks. Parallel optimization of viscosity reduction strategies and surfactant formulation is therefore recommended for robust formulation development.
Conclusion
The rheological properties of high-concentration mAb formulations are collectively governed by intermolecular electrostatic interactions and hydrophobic forces. Rational pH modulation, targeted supplementation of functional amino acid excipients (arginine and proline), and precise ionic strength tuning via salt screening constitute the core technical framework for effective viscosity control. Surfactants serve as auxiliary additives to optimize formulation stability and practical applicability. In industrial formulation development, single or combined modulation strategies should be tailored to the intrinsic physicochemical properties of individual mAb molecules, with comprehensive consideration of rheological performance, chemical and colloidal stability, osmolality, clinical administerability, and manufacturing compatibility. This integrated approach enables the rational development of high-performance high-concentration subcutaneous antibody formulations for clinical translation.
